

## Information for Authors

*Drug Research* accepts manuscripts in English covering drug research and development as well as the latest scientific findings on substances and/or products already marketed. The journal accepts manuscripts from the following areas: analytics applied to clinical trials, bioavailability, biochemistry, clinical and experimental pharmacology, drug interactions, efficacy testing, medicinal chemistry, pharmacodynamics, pharmacokinetics, systems pharmacology, toxicology and pre-clinical safety as well as questions relating to drug formulation, statistical methods for the evaluation of results from experimental investigations as well as clinical trials. Translational medicine aspects are key features of the journal: manuscripts dealing with pharmaceutical procedures to determine drug concentrations in biological fluids without any translational application in clinical studies and studies on novel compounds which are only tested in vitro will no longer be accepted. For the latter studies efficacy needs to be established at the animal level at least. Please note that bioequivalence studies are also no longer accepted. When submitted, manuscripts must not have been published elsewhere or be under simultaneous consideration by another journal. The aim of the journal is to disseminate new and reliable experimental data from across the field of drug research to researchers, scientists and doctors worldwide.

**N.B.: Incorrect English can result in the immediate rejection of your manuscript whereas correct English will help a speedy publication process.** It is in your own interest to ensure that your paper has been read by a native speaker of English; alternatively, you should use a copy-editing service like "American Journal Experts" if you have concerns about the English in your manuscript.

These types of manuscripts will be accepted:

- Original Articles
- Reviews
- Commentaries
- Controversies
- Opinion Papers
- Short Communications
- Letters

### Clinical Trials

The Journal supports trial registration. All trials reported must be registered at an official registry recognised by the International Committee of Medical Journal Editors, such as ClinicalTrials.gov ([www.clinicaltrials.gov](http://www.clinicaltrials.gov)) or any of the primary registries on the World Health Organization's International Clinical Trial Registry Platform ([www.who.int/ictrp](http://www.who.int/ictrp)). Please note: Clinical trials must be registered **before** recruitment of the first subject.

### Conflict of Interest

Please state the conflicts of interest of all authors.

During the online submission process, you will be asked to declare your conflicts of interest. Failure to do so or an incomplete declaration may result in non-publication.

### Ethics

The journal is very concerned about ethical standards. Please provide proof that the terms of the latest version of the "World Medical Association Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects" have been adhered to or provide approval of your local ethics committee. The same applies to animals. Please provide proof that experiments involving animals were carried out in compliance with the "Guide for the Care and Use of Laboratory animals" published by the National Academy of Sciences or else provide approval of your local ethics committee.

### Preprint Server Statement

*Drug Research* encourages the submission of manuscripts that have been deposited in an initial draft version in preprint repositories such as Research Square, arXiv, and medRxiv. Drafts of short conference abstracts or degree theses posted on the website of the degree-granting institution, and draft manuscripts deposited on authors' or institutional websites are also welcome. All other prior publication is forbidden.

During submission, authors should (1) note use of the preprint repository in the cover letter, (2) state what adjustments and/or updates the draft has undergone between deposition and submission and (3) cite the preprint, including the DOI, as a reference in the manuscript.

After submission to the journal, and until a final decision has been made, authors are discouraged from depositing versions of their manuscript as preprints. Upon publication authors should add a link from the preprint to the published article. Twelve months after publication, authors can update the preprint with the accepted manuscript.

### Manuscript Submission

All manuscripts must be submitted exclusively via online submission at <http://mc.manuscriptcentral.com/drugres>. Submissions of hardcopy manuscripts will not be accepted. Please include tables and figures as separate files, they should not be integrated into the main document, but a list with the legends of the figures and tables should be included there. Provide graphic files with sufficient resolution: coloured and black-white bitmaps: 300 dpi; diagrams and line drawings: 600 dpi minimum. Figures should be serially numbered with Arabic numerals. There should be a clear mark in the manuscript indicating where the figure should be inserted. Authors are responsible for the correctness of the manuscripts and the list of references. All measurements must be in Systeme International (SI) units.

#### Regarding the page limits in the following sections, please note:

- One printed page equals approx. 630 words. Small tables/figures (sized 1/4 of a page) reduce the number of words by approx. 150 words per table/figure, large tables/figures (sized 1/2 of a page) reduce the number of words by approx. 300 words per table/figure.

### A. Original Articles

Original papers should deal with investigations and results of high scientific value which have not been published previously.

1. Original papers should not exceed 9 printed pages, including references, tables, figures and legends. Please do not use more than one blank space between words and sentences.
2. Preparation of manuscripts  
Authors are asked to follow the outline set below:

Page 1: a) title, b) short running title (limit: 40 characters), c) name of the author (no titles or academic grades) and address of the institute(s) where the investigations have been carried out. Should the address of the author at the time of publication differ from the one stated in the paper, the current address should be stated in a footnote, d) complete mailing address of corresponding author including telephone and telefax numbers and e-mail addresses.

Page 2: a) a concise and comprehensive abstract detailing the key elements of the submitted paper (e. g. the background, the methods, the results and the major conclusion). The abstract should contain no more than 250 words with no abbreviations, b) key-words (3–6 without repeating words in the title).

Page 3 and onwards: a) introduction also indicating the aim of the study, b) materials and methods, c) results: double presentation of data in the form of text, tables or figures should be avoided, d) discussion and conclusions, e) list of references, f) legends of tables and figures. Do include your acknowledgements in the main document.

### 3. References

a) Text: Citations and references should be numbered consecutively using square brackets in the order in which they are cited in the text, followed by any in tables or legends. Please do not number references under alphabetical order of authors. Do not use footnotes and hyperlinks. If authors are mentioned in the text, only the first author should be given followed by “et al.” whenever the reference has three or more authors. Example: “...protein concentrations were determined according to Lowry et al. [1].”

b) *List of References*: References should be given as plain text. Do not use fields in MS Word, as these are difficult to process later. The references should be listed in numbered order according to the sequence they appear in the text. Preferably, all authors or groups of authors of each publication should be mentioned. The name of the author(s) should be followed by the full title of the paper, name of the journal in which it has been published (abbreviations according to “Index Medicus”), year of publication, volume, first and last page. Abstracts and supplements have to be indicated. Chapters from books have to be cited as follows: author(s), title of chapter, title of book, edi-

tor(s), place of publication, publisher, year of publication, first and last page of the chapter. See also the recommendations of the International Committee of Medical Journal Editors ([www.icmje.org](http://www.icmje.org)). Examples: 1 Park HY, Lim H, Pyo H, Kwon YS. Downregulation of matrix metalloproteinase-13 by the root extract of *Caythula officinalis* Kuan and its constituents in IL-1 $\beta$ -treated chondrocytes. *Planta Med* 2011; 75: 1528–1530  
2 Kerner W, Pfeiffer EF. The artificial pancreas. In: Samols E (ed). *The endocrine pancreas*. New York: Raven Press, 1991: 441–456

### B. Reviews

Reviews deal with previous research on a certain topic and serve to summarize current findings on the topic so far. The structure of the review will vary from an original paper according to the nature of the review, but please adhere to the guidelines concerning references. Please aim at no more than 8 printed pages including a maximum of 100 references.

### C. Commentaries

They usually follow the article that they discuss, have no special structure and are usually invited. They could also deal with an actual topic such as pivotal new scientific findings in the field. Commentaries should not exceed 2 printed pages, with a maximum of 20 references.

Please adhere to the reference guidelines outlined above.

### D. Opinion Papers, Controversies

The structure of these papers will vary from an original paper according to the nature of the topic and argument. Opinion papers present the authors’ comprehensive views on current developments in the area and discuss perspectives for the future. Controversies describe a relevant ongoing scientific dispute from an unbiased point of view. They should not exceed 3 printed pages, with a maximum of 40 references.

Please adhere to the guidelines concerning references outlined above.

### E. Short Communications

Short Communications are completed projects of smaller scope and should contain new clinical and experimental data of immediate interest.

1. They should not exceed 2 printed pages and may include 1 table and 1 figure. The list of references at the end of the paper should not exceed 10 citations.
2. The guidelines for the structure of Short Communications are the same as for Original Articles with the following exceptions:

- a) no keywords and b) no titles of the papers in the list of references.

### F. Letters

This section has been introduced to encourage authors to engage in a free exchange of ideas. The opinions presented do not necessarily reflect the opinions of the Editors.

### Page Charges

The publisher will impose a **page charge of 160 €** per printed page (including 19% VAT) **starting with the tenth page.**

### Figures: rights of use / copyright / personal rights

Unfortunately, we cannot accept images that have already been published in books, journals, or electronic products of other publishers. That is because it is almost impossible to obtain the necessary rights of use even when licensing fees are paid. Therefore, please do not pay any licensing fees (e.g. to “Right-Link” / Copyright Clearance Center). Standard license contracts from “Creative Commons” are unfortunately also insufficient for our purposes. Please contact us if you have any questions regarding the use of images.

### Proofs and Reprints as PDF File

Galley proofs will be sent to the corresponding author as a PDF file. At this stage of the production process, only minor corrections (typos, obvious errors in the production process) are accepted. **All other alterations will trigger a de-novo submission.**

The corresponding author receives a PDF file of the published article free of charge.

### Copyright

The publisher holds the copyright to all material appearing in the journal. A Copyright Transfer Agreement will be sent to the corresponding author together with the galley proofs. The agreement must be completed and returned to the publishers before the article can be published. Important: If you

intend to use material taken from foreign sources (including figures, tables, etc.), please contact the publisher directly to arrange the next steps ([drugresearch@thieme.de](mailto:drugresearch@thieme.de)).

**Editors-in-Chief**

Pharmacology & Toxicology  
Prof. Dr. med. Thomas Gudermann  
Ludwig-Maximilians-Universität München  
Walther-Straub-Institut für Pharmakologie  
und Toxikologie  
Goethestr. 33, 80336 München  
[thomas.gudermann@lrz.uni-muenchen.de](mailto:thomas.gudermann@lrz.uni-muenchen.de)

Clinical Pharmacology  
Prof. Dr. med. Matthias Schwab  
Dr. Margarete Fischer-Bosch-Institut für  
Klinische Pharmakologie  
Auerbachstr. 112, 70376 Stuttgart  
[matthias.schwab@ikp-stuttgart.de](mailto:matthias.schwab@ikp-stuttgart.de)